Alopecia

Alopecia areata shapes how people work, learn, and see themselves, a new occupational review finds, with barriers reaching far beyond hair loss.

New review guides hair loss care for transgender and gender-diverse patients, detailing how androgenic alopecia interacts with hormones and key therapies.

Three-year trial data show baricitinib sustains and deepens hair, eyebrow, and eyelash regrowth in severe alopecia areata, with stable long-term safety.

Meta-analysis finds alopecia areata links to lower melanoma odds and no added skin cancer risk despite ultraviolet-exposed scalp, informing Janus kinase inhibitor safety.

Phase 3 THRIVE-AA2 data show deuruxolitinib in alopecia areata boosts hair regrowth and satisfaction in severe AA, with manageable safety, vs placebo.

New evidence links alopecia areata and atopic dermatitis overlap, revealing eczema-like immune signatures and dual-use JAK/OX40 therapies to watch.

Black patients with breast cancer face cost, limited representation, and textured-hair concerns that reduce scalp-cooling use to prevent hair loss.

Deuruxolitinib shows consistent efficacy across subgroups and drives early hair regrowth in severe alopecia areata, with gains seen by 8 weeks.

Patients who saw hair specialist dermatologists tended to be prescribed more therapies for their scarring alopecia.

Topical immunotherapy remains an effective, affordable option for alopecia areata, with long-term control seen in multimodal treatment approaches.

Scalp tape strip samples had high concordance with lesion biopsies in patients with alopecia areata.

GPT-4o reliably scored alopecia areata severity from scalp images, showing strong concordance with experienced dermatology providers without prior AI training.

The tools are particularly helpful for pediatric patients, who often experience psychosocial impacts from the disease.

Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.

Study links moderate to severe alopecia areata to higher atopic dermatitis risk, urging routine screening and smarter treatment choices.

A global analysis found that although alopecia areata rates in young adults have modestly declined since 1990, the disease continues to disproportionately affect women and people in their early 30s.

Alopecia profoundly disrupts identity, emotional wellbeing, and social life, with many people struggling due to stigma, concealment pressures, and unmet psychological support needs.

New research suggests people with alopecia areata view hair regrowth efficacy as the most important factor when choosing a therapy, regardless of their disease severity.

Central centrifugal cicatricial alopecia (CCCA) faces significant diagnostic delays, highlighting the need for increased awareness and education among providers.

Patients with severe alopecia areata showed significantly elevated systemic inflammatory markers compared with mild disease and healthy controls.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

Alopecia areata significantly impacts quality of life, driven by appearance-related anxiety related to where hair loss occurs more than how much is lost.

Baricitinib shows promising results for severe alopecia areata, with more than half of patients experiencing significant hair regrowth within a year.

Early phototherapy significantly enhances hair regrowth in alopecia areata, especially when started within a year of symptom onset.